• 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚 (𝗔𝗳𝗼𝘅𝗼𝗹𝗮𝗻𝗲𝗿 + 𝗠𝗶𝗹𝗯𝗲𝗺𝘆𝗰𝗶𝗻 𝗢𝘅𝗶𝗺𝗲): 𝗔 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗔𝗻𝘁𝗶𝗽𝗮𝗿𝗮𝘀𝗶𝘁𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲
SPECTRA FOR DOGS 7.5–15 KG is a veterinary antiparasitic chewable formulation containing afoxolaner and milbemycin oxime. This weight-specific presentation is intended for dogs weighing more than 7.5 kg and up to 15 kg, subject to the applicable manufacturer's label. Afoxolaner belongs to the isoxazoline class and provides activity against susceptible fleas and ticks. Milbemycin oxime belongs to the macrocyclic lactone class and provides activity against susceptible nematode parasites.
The combination is designed to provide broad parasite coverage and can contribute to heartworm prevention when administered according to the approved veterinary regimen. The appropriate presentation should be selected based on the dog's current body weight. Veterinary guidance is recommended for puppies, breeding or pregnant animals, dogs with neurological conditions, or dogs receiving other medicines.
• 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚
1. Helps control susceptible flea infestations in dogs within the specified weight range.
2. Provides systemic activity against susceptible ticks.
3. Helps control susceptible gastrointestinal nematode infections.
4. Supports heartworm prevention when used according to the approved veterinary schedule.
5. Combines external and internal parasite control in a convenient oral chewable formulation.
• 𝗛𝗼𝘄 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚 𝗪𝗼𝗿𝗸𝘀
Afoxolaner acts on ligand-gated chloride channels in susceptible arthropods, including GABA-gated and glutamate-gated chloride channels, disrupting neuronal transmission and resulting in paralysis and death of susceptible fleas and ticks. Milbemycin oxime binds to glutamate-gated chloride channels in susceptible nematodes, increasing chloride-ion permeability and causing neuromuscular paralysis. This complementary mechanism allows the combination to provide activity against susceptible external and internal parasites, while milbemycin oxime contributes to heartworm prevention by acting against developing heartworm larvae when administered according to the approved regimen.
• 𝗨𝘀𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚
1. Dosage: Use the presentation intended for dogs weighing more than 7.5 kg and up to 15 kg. Follow the exact dosage and schedule stated on the approved product label.
2. Administration: Administer orally as a chewable tablet. Do not substitute a different weight-band presentation without veterinary advice.
3. Timing: For monthly parasite prevention, administer at the interval specified by the approved veterinary regimen and maintain the schedule consistently.
4. Monitoring: Observe the dog following administration and seek veterinary assessment if persistent or significant adverse signs occur.
5. Precautions: Accurately weigh the dog before treatment and consult a veterinarian before use in puppies, pregnant or lactating dogs, debilitated animals, or dogs with neurological disorders.
• 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚
1. Afoxolaner provides systemic activity against susceptible fleas and ticks.
2. Milbemycin oxime provides activity against susceptible gastrointestinal nematodes.
3. The combination offers coverage of multiple parasite groups through one oral veterinary formulation.
4. Regular administration can help maintain parasite prevention when the product is used according to the approved schedule.
5. The 7.5–15 kg presentation supports appropriate weight-based dosing for dogs within this body-weight range.
• 𝗢𝗳𝗳-𝗟𝗮𝗯𝗲𝗹 𝗨𝘀𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟳.𝟱–𝟭𝟱 𝗞𝗚
Off-label use means administering a veterinary medicine in a manner that differs from its approved label, such as for an unapproved indication, parasite, dosage regimen, or animal population. Such use should only be considered following an individual veterinary assessment.
1. A veterinarian may consider an alternative treatment regimen for a susceptible parasitic condition when supported by clinical evidence and professional judgment.
2. A veterinarian may use an active ingredient for a clinical circumstance not specifically listed on the local product label when clinically appropriate.
3. An alternative treatment strategy may occasionally be considered when standard labelled options are unsuitable for an individual dog.
• 𝗘𝘅𝗽𝗲𝗿𝘁 𝗔𝗱𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗽𝘁𝗶𝗺𝗮𝗹 𝗨𝘀𝗲
1. Confirm the dog's current body weight before selecting the 7.5–15 kg presentation.
2. Maintain the recommended dosing interval for ongoing parasite prevention.
3. Do not use a different weight-band tablet unless advised by a veterinarian.
4. Inform the veterinarian about all medicines, supplements, and other antiparasitic products the dog receives.
5. Dogs with a history of seizures or neurological disorders should be evaluated before receiving an isoxazoline-containing medicine.
6. Contact a veterinarian if significant vomiting, diarrhea, lethargy, tremors, ataxia, seizures, or other unexpected reactions occur after administration.
• 𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀
• 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗛𝗲𝗮𝗹𝘁𝗵
Dogs with significant cardiovascular disease should be assessed by a veterinarian before starting or changing an antiparasitic regimen. Dogs at risk of heartworm disease should receive appropriate preventive care, while suspected established heartworm infection requires veterinary diagnosis and management.
• 𝗟𝗶𝘃𝗲𝗿 & 𝗞𝗶𝗱𝗻𝗲𝘆 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻
Dogs with significant liver or kidney impairment should be evaluated by a veterinarian before treatment. The veterinarian can assess the animal's overall health and concurrent medications before deciding whether treatment is appropriate.
• 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 & 𝗕𝗿𝗲𝗮𝘀𝘁𝗳𝗲𝗲𝗱𝗶𝗻𝗴
Use during pregnancy or lactation should follow the specific product's approved veterinary information. Breeding animals should not receive treatment outside the labelled recommendations without veterinary guidance.
• 𝗗𝗿𝘂𝗴 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀
Tell the veterinarian about all prescription medicines, supplements, and other parasite-control products the dog is receiving. Avoid combining antiparasitic medicines without professional guidance.
• 𝗘𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀
Dogs with a history of seizures or neurological disorders should be evaluated before treatment. Isoxazoline-class medicines have been associated with neurological adverse reactions, including tremors, ataxia, and seizures, in some animals.
• 𝗦𝘁𝗼𝗿𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀
1. Store according to the manufacturer's labelled storage conditions.
2. Keep the chewable tablets in their original packaging until administration.
3. Protect the product from excessive heat, moisture, and direct sunlight.
4. Keep out of reach of children and animals for which the medicine was not intended.
5. Do not use the product after its expiry date or if the packaging is damaged.
• 𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 (𝗙𝗔𝗤𝘀)
• Q: What is SPECTRA FOR DOGS 7.5–15 KG?
A: SPECTRA FOR DOGS 7.5–15 KG is a veterinary antiparasitic chewable formulation containing afoxolaner and milbemycin oxime for dogs weighing more than 7.5 kg and up to 15 kg, according to the applicable product label.
• Q: What are the active ingredients in SPECTRA FOR DOGS?
A: The active ingredients are afoxolaner and milbemycin oxime. The exact strength should be confirmed from the manufacturer's packaging and locally approved product information.
• Q: What parasites does SPECTRA FOR DOGS help control?
A: Depending on the approved indication, the combination provides activity against susceptible fleas, ticks, gastrointestinal nematodes, and contributes to heartworm prevention.
• Q: How often is SPECTRA FOR DOGS administered?
A: For indications requiring ongoing prevention, it is generally administered once monthly according to the approved veterinary dosing schedule.
• Q: Can SPECTRA FOR DOGS be given to puppies?
A: Puppy eligibility depends on age, body weight, health status, and the applicable product label. A veterinarian should confirm whether the product is appropriate for a particular puppy.
• Q: Can SPECTRA FOR DOGS be used in dogs with seizures?
A: Dogs with a history of seizures or neurological disorders should be evaluated by a veterinarian before treatment because neurological adverse reactions have been reported with isoxazoline-class medicines.
• Q: Is SPECTRA FOR DOGS a prescription medicine?
A: Regulatory status varies between countries and jurisdictions. Follow the applicable local veterinary prescription, dispensing, and administration requirements.
